ClinicalTrials.gg
RecruitingNCT04751396Updated Nov 12, 2026

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

An observational study in Ankylosing Spondylitis, Autoimmune Disease and Crohn Disease, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.

Planned enrollment
22nd of 28
125 · median 445
Started
2022
the only one that year
Observational
28 of 87
9 open now
Primary completion
2027-02
later than 6 of 11 live
Registered
72nd of 87
by date

Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 22nd largest by planned enrollment of the 28 observational ones that give a count, is the only one that started in 2022, is one of 28 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 72nd registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Spondylitis, Ankylosing with a site in United States, or all of them as a file.
02

Study summary

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the acceptability (e.g., ease of use, design, accessibility, content) of the educational tool that will be developed for patients with melanoma and pre-existing autoimmune conditions considering or undergoing treatment with immune checkpoint inhibitors.

II. To test the usability in real world-settings of the educational tool (to be developed) and evaluate feasibility of patient recruitment (i.e., ability to identify enough patients and consent at least 50% of the identified patients) in a pilot study.

OUTLINE:

PART A: Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.

PART B: 2 group of participants will be evaluated sequentially (Participants in group II will be enrolled after all the participants in group I have been assessed).

GROUP I: Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.

GROUP II: Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.

03

Conditions studied

  • Ankylosing Spondylitis
  • Autoimmune Disease
  • Crohn Disease
  • Enteropathic Arthritis
  • Enteropathic Spondylitis
  • Inflammatory Bowel Disease
  • Melanoma
  • Psoriasis
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with melanoma or pre-existing autoimmune disease and clinicians

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of melanoma
  • Diagnosis of pre-existing disease

    • Inflammatory bowel disease

      • Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist
      • For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically
      • Treatment with aminosalicylates, , thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists)
    • Rheumatoid arthritis

      • Diagnosis of rheumatoid arthritis by a rheumatologist
      • Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy
    • Systemic lupus erythematosus

      • Diagnosis of systemic lupus erythematosus by a rheumatologist
    • Psoriasis

      • Diagnosis of psoriasis by a dermatologist
      • Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies
    • Spondyloarthropathies

      • Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis/spondylitis by a rheumatologist
      • Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy
  • Age of 18 years or older
  • Patients whose physicians had recommended they begin using any of the currently available or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor
  • E-mail access and computer with Internet access or telephone
  • Ability to communicate in English or Spanish
  • CLINICIAN
  • Prescribed immune checkpoint inhibitors
  • Are providing care for patients with melanoma
  • In the clinics at MD Anderson
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)

Groups and cohorts

  • Part A (Interview)

    Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.

    Other: Educational Intervention · Other: Interview

  • Part B Group I (standard information)

    Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.

    Other: Best Practice · Other: Questionnaire Administration · Other: Survey Administration

  • Part B Group II (educational tool)

    Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.

    Other: Educational Intervention · Other: Questionnaire Administration · Other: Survey Administration

Interventions

  • OtherBest Practice

    Receive standard educational information

    Also known as: standard of care, standard therapy

  • OtherEducational Intervention

    Navigate educational tool

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherInterview

    Participate in interview

  • OtherQuestionnaire Administration

    Complete questionnaire

  • OtherSurvey Administration

    Complete surveys

06

What researchers measure

Primary outcomes

  1. Decisional conflict scale

    The scale will be used to assess personal perceptions of 1) uncertainty in choosing among options; 2) modifiable factors contributing to uncertainty, such as feeling uninformed, and 3) feeling that the choice is values-based and likely to be implemented.

    Time frame: Up to 4 years

Secondary outcomes

  1. Knowledge

    Will be assessed using a questionnaire developed by the research team covering various content areas, including general information about immune checkpoint inhibitors and the associated adverse effects and benefits of the treatments.

    Time frame: Up to 3 months

  2. Acceptability

    A standard assessment questionnaire will be used to obtain users' ratings of various features of the educational tool, including ease of use, presentation, usefulness and satisfaction. The items in the questionnaire come from the Ottawa Acceptability Measures.

    Time frame: Immediately after the clinical encounter

  3. Usability

    A standard assessment questionnaire will be used to obtain users' ratings of various features of the educational tool, including ease of use, presentation, usefulness and satisfaction. The items in the questionnaire come from the Ottawa Acceptability Measures.

    Time frame: Immediately after the clinical encounter

  4. Depression

    Will be assessed using the Depression and Anxiety Stress Scale (DASS). The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia

    Time frame: Up to 3 months

  5. Anxiety

    Will be assessed using the DASS. The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect.

    Time frame: Up to 3 months

  6. Stress

    Will be assessed using the DASS. The DASS is a 21-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. The Stress scale is sensitive to levels of chronic non-specific arousal. It assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient.

    Time frame: Up to 3 months

  7. CollaboRATE measure

    The CollaboRATE questions ask about the effort made to help patients understand their health issues, listen to what matters most to them, and include what matters most to them in choosing what to do next.

    Time frame: Immediately after the clinical encounter

  8. Shared decision-making process survey

    This instrument measures the extent to which health care providers engage patients in shared decision making. Items are focused on four specific behaviors that are critical for shared decision making -discussion of options, pros, cons and preferences.

    Time frame: Immediately after the clinical encounter

  9. Patient's perception of usefulness of the tool

    Will use the Preparation for Decision Making Scale (Prep-DM) to assess the patients' perception of how useful the educational tool is in preparing them to communicate with their practitioner at a consultation. It is a 10-item scale developed to evaluate decision processes relating to the preparation of patients for decision making and dialoguing with their practitioners.

    Time frame: Immediately after the clinical encounter

07

Study locations

1 of 1 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Maria A. Lopez-Olivo · Contact713-792-9175
    • Maria A. Lopez-Olivo · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Feb 2027, 57 months after the start.

Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 57 months is below that.

Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
Apr 20, 2022
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04751396
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Apr 20, 2022
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Angeles Lopez-Olivo
Contact
amlopezo@mdanderson.org
713-792-9175
Angeles Lopez-Olivo
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion